Combination therapies with mitogen-activated protein kinase kinase inhibitors and immune checkpoint inhibitors in non-small cell lung cancer

According to the most common co-mutations including serine/threonine kinase 11/liver kinase B1, TP53 and cyclin-dependent kinase inhibitor 2A/B inactivation, KRAS-mutant NSCLC has been classified into three subsets: KL, KP, and KC. [15] Response to MEKi may also be different due to downstream activation of AKT or signal transducer and activator of transcription 3. [...]a proper signature predicting the response to combination therapies with MEKi and checkpoint inhibitors is required in KRAS-mutant NSCLC. [...]optimization strategies of combination therapies in NSCLC need further evaluation.